Regulatory Shift in Cannabis Impacts Tillray
about 1 month ago
Carol Master
"Oh, it's a surprise. It's a surprise because we know President Trump's signing an executive order um changing the drug classification for cannabis to move cannabis into a less restrictive federal category. So, I'm looking at Tillray and Canopy, Tillray, T LR Y, and Canopy CGC. But both shares are edging lower by 1.3% and 3 and a half% respectively, which was priced in."
The speaker highlights a regulatory catalyst as President Trump's executive order stands to shift cannabis into a category reserved for drugs with accepted medical uses. Tillray is mentioned specifically alongside Canopy, with current market moves already reflecting the news.
Scores
Alpha Potential
7.0/10
Novelty
7.0/10
Credibility
7.0/10
Timeliness
6.0/10
Overall
7.0/10
Sentiment
Neutral/Mixed
Conviction
Medium
Tier
Company Commentary
Related Stocks
Episode Information
Episode:
Marijuana Stocks Fall, Micron Jumps, Lululemon Surges | Stock Movers
Source:
Stock Movers
Published:
December 18, 2025
Idea Type:
Regulatory Insight